

CITATION REPORT

List of articles citing

Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate

DOI: 10.1136/annrheumdis-2017-212172

Annals of the Rheumatic Diseases, 2018, 77, 488-494.

Source: <https://exaly.com/paper-pdf/69184433/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
22	Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study. <i>RMD Open</i> , 2018 , 4, e000757	5.9	18
21	Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2018 , 20, 84	4.9	17
20	Nocebos in rheumatology: emerging concepts and their implications for clinical practice. <i>Nature Reviews Rheumatology</i> , 2018 , 14, 727-740	8.1	47
19	Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study. <i>Arthritis Research and Therapy</i> , 2019 , 21, 122	5.7	5
18	The future landscape of biosimilars in rheumatology: Where we are where we are going. <i>Autoimmunity Reviews</i> , 2019 , 18, 203-208	13.6	4
17	Drug survival rates of biological disease-modifying antirheumatic drugs and Janus kinase-inhibitor therapy in 801 rheumatoid arthritis patients: a 14 year-retrospective study from a rheumatology clinic in Japan. <i>Modern Rheumatology</i> , 2019 , 29, 928-935	3.3	5
16	Anti-tumor necrosis factor biosimilars and intended copies in rheumatology: Perspective from the Asia Pacific region. <i>International Journal of Rheumatic Diseases</i> , 2019 , 22, 9-24	2.3	3
15	Orthogonal Middle-up Approaches for Characterization of the Glycan Heterogeneity of Etanercept by Hydrophilic Interaction Chromatography Coupled to High-Resolution Mass Spectrometry. <i>Analytical Chemistry</i> , 2019 , 91, 873-880	7.8	21
14	A randomized double-blind parallel-group phase III study to compare the efficacy and safety of NI-071 and infliximab reference product in Japanese patients with active rheumatoid arthritis refractory to methotrexate. <i>Modern Rheumatology</i> , 2019 , 29, 919-927	3.3	10
13	Additional response to the correspondence: Switching from the bio-originators to biosimilar: is it premature to recommend this procedure? by Cantini and Bennuci. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e26	2.4	3
12	Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents. <i>BioDrugs</i> , 2020 , 34, 27-37	7.9	19
11	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 760-770	2.4	112
10	Nanoparticle-siRNA: A potential strategy for rheumatoid arthritis therapy?. <i>Journal of Controlled Release</i> , 2020 , 325, 380-393	11.7	11
9	Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 744-759	2.4	75
8	Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis. <i>Expert Review of Clinical Immunology</i> , 2021 , 17, 85-99	5.1	8
7	LBEC0101, an etanercept biosimilar for the treatment of rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 1-8	5.4	
6	Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. <i>Modern Rheumatology</i> , 2021 , 1-13	3.3	1

5	The global landscape on interchangeability of biosimilars. <i>Expert Opinion on Biological Therapy</i> , 2021 , 1-16	5.4	2
4	Comparative efficacy and safety of tumor necrosis factor inhibitors and their biosimilars in patients with rheumatoid arthritis having an insufficient response to methotrexate : A network meta-analysis. <i>Zeitschrift Fur Rheumatologie</i> , 2021 , 1	1.9	0
3	Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept. <i>BioDrugs</i> , 2021 , 35, 765-772	7.9	
2	Rehabilitation Treatment for the Surgery of Lower Extremity in the Patients with Rheumatoid Arthritis. <i>The Japanese Journal of Rehabilitation Medicine</i> , 2020 , 57, 1039-1046	0	
1	Efficacy, safety and immunogenicity of etanercept biosimilars versus reference biologics in patients with rheumatoid arthritis: A meta-analysis. 14,		0